Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Am J Med. 2016 Jun 2;129(10):1067–1073. doi: 10.1016/j.amjmed.2016.05.008

Figure 2.

Figure 2

Kaplan-Meier plots displaying association between pre-discharge initiation of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blocker (ARBs) and 30-day all-cause readmission in a propensity-matched cohort of hospitalized Medicare beneficiaries with heart failure and left ventricular ejection fraction <45%. (CI=confidence interval)